Drug Trial Radar · NCT01065454
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
202
Actual
Start
Apr 14, 2010
Primary completion
Jun 6, 2012
Study completion Jul 23, 2025
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Feb 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
Conditions
- Hypertension, Pulmonary
- Ventricular Dysfunction, Left
Interventions
Riociguat (Adempas, BAY63-2521)Drug
up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
Riociguat (Adempas, BAY63-2521)Drug
up to 1 mg three times a day (increasing from 0.5 to 1 mg)
Riociguat (Adempas, BAY63-2521)Drug
fixed 0.5 mg three times a day
PlaceboDrug
Placebo three times a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pulmonary Artery Mean Pressure (PAPmean) at Rest - Change From Baseline to Week 16Time frame: Baseline and visit 6 (16 weeks)
Locations
83 sites in 18 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
San Diego, California
Site not named
Torrance, California
Site not named
Westminster, California
Site not named
Miami, Florida
Site not named
Iowa City, Iowa
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Rochester, Minnesota
Site not named
St Louis, Missouri
Site not named
Cincinnati, Ohio
Site not named
Fairfield, Ohio
Site not named
Falls Church, Virginia
Site not named
Milwaukee, Wisconsin
Site not named
Sydney, New South Wales, Australia
Site not named
Herston, Queensland, Australia
Site not named
Melbourne, Victoria, Australia
Site not named
Vienna, State of Vienna, Austria
Site not named
Innsbruck, Tyrol, Austria
Site not named
Aalst, Belgium
Site not named
Brussels, Belgium
Site not named
Ghent, Belgium
Site not named
Leuven, Belgium
Site not named
Edmonton, Alberta, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Québec, Quebec, Canada
Site not named
Beijing, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Brno, Czechia
Site not named
Olomouc, Czechia
Site not named
Prague, Czechia
Site not named
Prague, Czechia
Site not named
Aarhus N, Denmark
Site not named
Bron, France
Site not named
Lille, France
Site not named
Nantes, France
Site not named
Pessac, France
Site not named
Rouen, France
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.